Structure Therapeutics ACCESS data validates ‘bull case,’ says H.C. Wainwright

After Structure Therapeutics (GPCR) released pivotal topline data from the Phase 2b ACCESS program, H.C. Wainwright argues that the clean safety profile along with 15.3% placebo-adjusted weight loss at the 240 mg dose shatters the “oral ceiling,” exceeding the roughly 12.4% efficacy benchmark set by Eli Lilly’s (LLY) orforglipron. The firm, which sees the data validating the “bull case” thesis the firm previously outlined, has a Buy rating and $60 price target on Structure shares.